- $482.91m
- $700.70m
- $65.12m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 7.42 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -35.22% | ||
| Return on Equity | n/a | ||
| Operating Margin | -69.48% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 0.18 | 11.99 | 65.12 | 82.68 | 111.56 | 1807.41% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 24th, 2024
- Public Since
- January 30th, 2025
- No. of Shareholders
- 794
- No. of Employees
- 291
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 43,348,840
- Address
- 11 Hughes, IRVINE, 92618
- Web
- https://www.betabionics.com
- Phone
- +1 9494277785
- Contact
- Blake Beber
- Auditors
- Ernst & Young LLP
Upcoming Events for BBNX
Q1 2025 Beta Bionics Inc Earnings Call
Beta Bionics Inc To Host Investor Event
Similar to BBNX
908 Devices
NASDAQ Global Market
Alpha Teknova
NASDAQ Global Market
Anteris Technologies Global
NASDAQ Global Market
AtriCure
NASDAQ Global Market
Brainsway
NASDAQ Global Market
FAQ
What is the Beta Bionics share price?
As of Today at 19:34 UTC, shares in Beta Bionics are trading at $11.14. This share price information is delayed by 15 minutes.
How has the Beta Bionics share price performed this year?
Shares in Beta Bionics last closed at $11.14 and the price had moved by over the past 365 days. In terms of relative price strength the Beta Bionics share price has matched the S&P500 Index by over the past year.
What are the analyst and broker recommendations for Beta Bionics?
The overall consensus recommendation for Beta Bionics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Beta Bionics dividend yield?
Beta Bionics does not currently pay a dividend.
Does Beta Bionics pay a dividend?
Beta Bionics does not currently pay a dividend.
When does Beta Bionics next pay dividends?
Beta Bionics does not currently pay a dividend.
How do I buy Beta Bionics shares?
To buy shares in Beta Bionics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Beta Bionics?
As of the previous close price of $11.14, shares in Beta Bionics had a market capitalisation of $482.91m.
Where are Beta Bionics shares listed?
Here are the trading details for Beta Bionics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: BBNX
What kind of share is Beta Bionics?
Based on an overall assessment of its quality, value and momentum Beta Bionics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Beta Bionics share price forecast for 2025?
The analyst consensus target price for shares in Beta Bionics is $25.71. That is 130.79% above the last closing price of $11.14.
Analysts covering Beta Bionics currently have a consensus Earnings Per Share (EPS) forecast of -$1.84 for the next financial year.
Find out moreWhat is the trend in the Beta Bionics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Beta Bionics. Over the past six months, its share price has matched the S&P500 Index by .
As of the last closing price of $11.14, shares in Beta Bionics were trading -33.66% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Beta Bionics PE Ratio?
The Beta Bionics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $11.14.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Beta Bionics?
We do not have data on Beta Bionics' directors